We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MIMETAS Develops Novel Gut-On-A-Chip Technology in Collaboration with Pharmaceutical Company
Product News

MIMETAS Develops Novel Gut-On-A-Chip Technology in Collaboration with Pharmaceutical Company

MIMETAS Develops Novel Gut-On-A-Chip Technology in Collaboration with Pharmaceutical Company
Product News

MIMETAS Develops Novel Gut-On-A-Chip Technology in Collaboration with Pharmaceutical Company

Image Credit: MIMETAS

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "MIMETAS Develops Novel Gut-On-A-Chip Technology in Collaboration with Pharmaceutical Company"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MIMETAS, in collaboration with the pharmaceutical company Roche (Basel), has developed a novel organ-on-a-chip system that supports evaluation of intestinal permeability in perfused 3D gut tubules in high throughput. The results of this research were published this week in the leading scientific journal Nature Communications.

In this publication, MIMETAS and Roche scientists report growing over 350 gut tubules under flow that formed leak-tight structures and could be interrogated for intestinal barrier function in real-time using automated microscopy and image analysis. The intestinal tubules were polarized and leak-tight after only 4 days in culture and showed increased expression of specific transporters and receptors. This gut model lends itself to toxicology, transport and disease modeling studies, as well as fundamental research on the intestinal barrier.

Paul Vulto, Managing Director of MIMETAS and senior author on the paper, comments: “This article in a major journal shows the world what the OrganoPlate® platform is capable of. With 350 gut tubes and over 20,000 data points measured, this is the largest organ-on-achip dataset ever published. It demonstrates that 3D cell culture under perfusion flow isn’t necessarily complex to do. In fact, every cell biologist is now able to work with OrganoPlates® and reproduce our results”.

According to Vulto, the Nature Communications paper shows only the tip of the iceberg: “Scientists at MIMETAS and elsewhere around the world are developing stunning 3D cell culture models in the OrganoPlate® platform every day. The fact that one can culture tubules, blood vessels, and tissue co-cultures in 3D, without artificial membranes and with an unprecedented imaging quality, enables researchers to study human tissue biology in a completely novel way. We are proud to support these fantastic scientists in their search for ever more physiologically relevant tissue models. We are now making this technology available to every scientist in the world”. 


Advertisement